Pfizer Exec Urges National People’s Congress To Adopt Diversified Funding Mechanism For Biologics, Targeted Cancer Therapies
This article was originally published in PharmAsia News
Pfizer Inc.’s China Corporate Affairs Director Danlong Feng is the first executive from a multinational firm in China to serve as a delegate at the annual Chinese People’s Political Consultative Conference. Feng called on government, drug makers and insurers to create diversified funding mechanisms to widen access to innovative therapies in China.
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.